TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06630411: ENGAGE-PSMA: Phase 1b/2 Dose Expansion of JANX007 Tumor-Activated PSMAxCD3 T-Cell Engager in mCRPC

Sponsor: Janux Therapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 160 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT06630411 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06630411 Rescue Dossier →